Interleukin-12 Message in a Bottle

被引：8
|
作者：
Cirella, Assunta [1 ,2 ]
Berraondo, Pedro [1 ,2 ,3 ]
Di Trani, Claudia Augusta [1 ,2 ]
Melero, Ignacio [1 ,2 ,3 ,4 ]
机构：
[1] Cima Univ Navarra, Program Immunol & Immunotherapy, Pamplona, Spain
[2] Navarra Inst Hlth Res IDISNA, Pamplona, Spain
[3] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[4] Clin Univ Navarra, Dept Immunol & Immunotherapy, Pamplona, Spain
来源：
CLINICAL CANCER RESEARCH | 2020年 / 26卷 / 23期
基金：
欧盟地平线“2020”;
关键词：
D O I：
10.1158/1078-0432.CCR-20-3250
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IL12 is a very potent cancer immunotherapy agent, but is difficult to harness safely if given systemically. Local gene transfer aims to confine the effects of IL12 to malignant tissues, thus avoiding toxicity. Lipid-nanoparticle mRNA achieves IL12 expression and efficacy in mouse models, opening the way to an ongoing trial.
引用
收藏
页码：6080 / 6082
页数：3
相关论文
共 50 条
  • [21] MOLECULAR CHARACTERIZATION OF INTERLEUKIN-12
    PODLASKI, FJ
    NANDURI, VB
    HULMES, JD
    PAN, YCE
    LEVIN, W
    DANHO, W
    CHIZZONITE, R
    GATELY, MK
    STERN, AS
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1992, 294 (01) : 230 - 237
  • [22] Interleukin-12 in human milk
    Bryan, DL
    Hawkes, JS
    Gibson, RA
    PEDIATRIC RESEARCH, 1999, 45 (06) : 858 - 859
  • [23] Genetic evidence for the existence of interleukin-23 and for variation in the interleukin-12 and interleukin-12 receptor genes in the horse
    Kralik, Petr
    Matiasovic, Jan
    Horin, Petr
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY D-GENOMICS & PROTEOMICS, 2006, 1 (02): : 179 - 186
  • [24] Interleukin-12 in Human Milk
    Dani-Louise Bryan
    Joanna S Hawkes
    Robert A Gibson
    Pediatric Research, 1999, 45 : 858 - 859
  • [25] THE INTERLEUKIN-12 SUBUNIT P40 SPECIFICALLY INHIBITS EFFECTS OF THE INTERLEUKIN-12 HETERODIMER
    MATTNER, F
    FISCHER, S
    GUCKES, S
    JIN, SC
    KAULEN, H
    SCHMITT, E
    RUDE, E
    GERMANN, T
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (09) : 2202 - 2208
  • [26] Immunobiological effects of interleukin-2, interleukin-12 or interleukin-2 plus interleukin-12 in metastatic cancer patients
    Lissoni, P
    Barni, S
    Mandala, M
    Rovelli, F
    Cangemi, G
    Fumagalli, L
    Pirato, D
    Vigore, L
    Roselli, MG
    Tancini, G
    Vigano, MG
    Giani, L
    INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, 1998, 14 (01): : 41 - 44
  • [27] Characterization of mouse interleukin-12 p40 homodimer binding to the interleukin-12 receptor subunits
    Wang, X
    Wilkinson, VL
    Podlaski, FJ
    Wu, CY
    Stern, AS
    Presky, DH
    Magram, J
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1999, 29 (06) : 2007 - 2013
  • [28] Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo
    Gately, MK
    Carvajal, DM
    Connaughton, SE
    Gillessen, S
    Warrier, RR
    Kolinsky, KD
    Wilkinson, VL
    Dwyer, CM
    Higgins, GF
    Podlaski, FJ
    Faherty, DA
    Familletti, PC
    Stern, AS
    Presky, DH
    INERLEUKIN 12: CELLULAR AND MOLECULAR IMMUNOLOGY OF AN IMPORTANT REGULATORY CYTOKINE, 1996, 795 : 1 - 12
  • [29] Interleukin-12 and interleukin-16 in periodontal disease
    Tsai, IS
    Tsai, CC
    Ho, YP
    Ho, KY
    Wu, YM
    Hung, CC
    CYTOKINE, 2005, 31 (01) : 34 - 40
  • [30] Cancer Electrogene Therapy with Interleukin-12
    Cemazar, Maja
    Jarm, Tomaz
    Sersa, Gregor
    CURRENT GENE THERAPY, 2010, 10 (04) : 300 - 311
12345